Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial
Zhao et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107702
https://c19early.org/zhao2.html